|
시장보고서
상품코드
1842182
AAV 위탁개발생산기관 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 배양별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)AAV Contract Development And Manufacturing Organizations Market Size, Share & Trends Analysis Report By Workflow (Upstream Processing, Downstream Processing), By Culture, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
AAV 위탁개발생산기관 시장 요약
세계의 AAV 위탁개발생산기관 시장 규모는 2024년에 8억 6,270만 달러로 평가되었으며, 2033년에는 34억 9,030만 달러에 달할 것으로 예측되며, 2025년부터 2033년까지 CAGR은 16.50%로 성장할 것으로 예측됩니다.
이 시장을 주도하는 것은 유전자 치료 용도, 특히 희귀 유전 질환, 안과 질환, 신경 질환 치료에서 아데노 부속 바이러스(AAV) 벡터에 대한 수요가 증가하고 있기 때문입니다.
규제 당국의 AAV 기반 치료제의 승인 증가는 전문 제조 능력의 필요성을 더욱 가속화시키고 있습니다. 이 시장은 주로 세포-유전자 치료제 파이프라인에 대한 R&D 투자가 급증하면서 AAV CDMO에 대한 의존도가 높아지고 있습니다. 중소규모의 생명공학 기업들은 자체적으로 벡터 개발 능력이 없는 경우가 많기 때문에 아웃소싱은 비용 효율적이고 효율적인 솔루션이 될 수 있습니다. 개발 CDMO는 첨단 바이러스 벡터 제조 시설을 건설하고, 자동화 플랫폼을 통합하고, 공정 개발, GMP 제조, 약사법 지원을 포함한 엔드 투 엔드 서비스를 제공함으로써 그 역량을 확장하고 있습니다. 이러한 서비스 포트폴리오의 확장은 시장에 강력한 성장 기회를 제공하고 있습니다.
본 보고서의 참고자료를 원하시는 분은 무료 샘플판을 요청해 주시기 바랍니다.
또한, 론자, 캐터런트, 써모피셔 사이언티픽, 삼성바이오로직스 등 주요 기업들의 전략적 제휴 및 역량 확대로 시장 경쟁력이 강화되고 있습니다. 유전성 및 희귀질환의 유병률 증가와 AAV 기반 치료법을 평가하는 임상시험의 증가는 아웃소싱 수요를 더욱 증가시키고 있습니다. 이러한 역동성으로 인해 AAV CDMO는 유전자 치료 생태계의 중요한 중추로 자리매김하여 임상 및 상업용 고품질 바이러스 벡터의 적시 공급을 보장하고 있습니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 AAV 위탁개발생산기관 시장 : 변수, 동향, 범위
- 시장 계통 전망
- AAV 위탁개발생산기관 시장 역학
- 기술적 상황
- 가격 모델 분석
- AAV 위탁개발생산기관 시장 : 분석 툴
제4장 AAV 위탁개발생산기관 시장 : 워크플로우별 추정·동향 분석
- 부문 대시보드
- 세계의 AAV 위탁개발생산기관 시장 : 워크플로우별 변동 분석
- 세계의 AAV 위탁개발생산기관 시장 규모와 동향 분석 : 워크플로우별, 2021-2033년
- 업스트림 처리
- 벡터 증폭과 확장
- 벡터 회수와 수확
- 다운스트림 처리
- 정제
- 충전 마감
제5장 AAV 위탁개발생산기관 시장 : 배양별 추정·동향 분석
- 부문 대시보드
- 세계의 AAV 위탁개발생산기관 시장 : 배양별 변동 분석
- 세계의 AAV 위탁개발생산기관 시장 규모와 동향 분석 : 배양별, 2021-2033년
- 부착 배양
- 현탁 배양
제6장 AAV 위탁개발생산기관 시장 : 용도별 추정·동향 분석
- 부문 대시보드
- 세계의 AAV 위탁개발생산기관 시장 : 용도별 변동 분석
- 세계의 AAV 위탁개발생산기관 시장 규모와 동향 분석 : 용도별, 2021-2033년
- 세포 및 유전자 치료 개발
- 백신 개발
- 바이오의약품 및 의약품 발견
- 바이오메디컬 조사
제7장 AAV 위탁개발생산기관 시장 : 최종 용도별 추정·동향 분석
- 부문 대시보드
- 세계의 AAV 위탁개발생산기관 시장 : 최종 용도 변동별분석
- 세계의 AAV 위탁개발생산기관 시장 규모와 동향 분석 : 최종 용도별, 2021-2033년
- 제약회사 및 바이오의약품 회사
- 학술조사기관
제8장 AAV 위탁개발생산기관 시장 : 지역별 추정·동향 분석
- 시장 대시보드 : 지역별
- 시장 현황 : 지역별
- 시장 규모, 예측 동향 분석 : 2021-2033년
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
- 오만
- 카타르
제9장 경쟁 구도
- 기업 분류
- AAV 위탁개발생산기관 시장 점유율 분석, 2024년
- 기업 개요
- Thermo Fischer Scientific, Inc.
- Creative Biogene
- Catalent Inc
- Charles River Laboratories International, Inc
- Danaher(Aldevron)
- Forge Biologics
- Genezen
- ViroCell Biologics
- Merck KGaA
- VIRALGEN
- Biovian Oy
- Esco Lifesciences(Esco Aster Pte. Ltd.)
- GenScript ProBio
- Porton Advanced Solution Ltd
- Ask Bio
- Showa Denko
- Takara Bio, Inc.
- ABL Manufacturing
- Oxford Biomedica
- Belief Biomed, Inc.
- Beijing Anlong Biomedicine Co., Ltd
- Forecyte Bio Limited
- Gene Pharma, Inc.
- Skyline Therapeutics
- TFBS Bioscience, Inc
AAV Contract Development And Manufacturing Organizations Market Summary
The global AAV contract development and manufacturing organizations market size was estimated at USD 862.7 million in 2024 and is projected to reach USD 3,490.3 million by 2033, growing at a CAGR of 16.50% from 2025 to 2033. The market is driven due to the rising demand for adeno-associated virus (AAV) vectors in gene therapy applications, particularly in the treatment of rare genetic disorders, ophthalmic conditions, and neurological diseases.
Increasing approvals of AAV-based therapies by regulatory bodies have further accelerated the need for specialized manufacturing capacity. The market is primarily driven by thesurge in R&D investments in cell and gene therapy pipelines and is also fueling the reliance on AAV CDMOs. Small and mid-sized biotech firms often lack in-house vector development capabilities, making outsourcing a cost-effective and efficient solution. Leading CDMOs are expanding their capabilities by building advanced viral vector manufacturing facilities, integrating automated platforms, and offering end-to-end services including process development, GMP manufacturing, and regulatory support. This expansion of service portfolios is creating strong growth opportunities for the market.
To learn more about this report, request a free sample copy
Furthermore, strategic partnerships and capacity expansions by key players such as Lonza, Catalent, Thermo Fisher Scientific, and Samsung Biologics are enhancing market competitiveness. The growing prevalence of genetic and rare diseases, coupled with an increasing number of clinical trials evaluating AAV-based therapies, is further driving outsourcing demand. These dynamics position AAV CDMOs as a critical backbone of the gene therapy ecosystem, ensuring a timely supply of high-quality viral vectors for both clinical and commercial use.
Global AAV Contract Development And Manufacturing Organizations Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AAV contract development and manufacturing organizations market report based on workflow, culture, application, end use, and region.
- Workflow Outlook (Revenue, USD Million, 2021 - 2033)
- Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery & Harvesting
- Downstream Processing
- Purification
- Fill Finish
- Culture Outlook (Revenue, USD Million, 2021 - 2033)
- Adherent Culture
- Suspension Culture
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Cell & Gene Therapy Development
- Vaccine Development
- Biopharmaceutical and Pharmaceutical Discovery
- Biomedical Research
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical and Biopharmaceutical Companies
- Academic & Research Institutes
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. AAV Contract Development And Manufacturing Organizations Market: Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. AAV Contract Development And Manufacturing Organizations Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Technological Landscape
- 3.4. Pricing Model Analysis
- 3.5. AAV Contract Development And Manufacturing Organizations Market: Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis
Chapter 4. AAV Contract Development And Manufacturing Organizations Market: Workflow Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global AAV Contract Development And Manufacturing Organizations Market Workflow Movement Analysis
- 4.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
- 4.4. Upstream Processing
- 4.4.1. Upstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD million)
- 4.4.2. Vector Amplification & Expansion
- 4.4.2.1. Vector Amplification & Expansion Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Vector Recovery & Harvesting
- 4.4.3.1. Vector Recovery & Harvesting Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Downstream Processing
- 4.5.1. Downstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.2. Purification
- 4.5.2.1. Purification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Fill Finish
- 4.5.3.1. Fill Finish Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. AAV Contract Development And Manufacturing Organizations Market: Culture Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global AAV Contract Development And Manufacturing Organizations Market Culture Movement Analysis
- 5.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by Culture, 2021 to 2033 (USD Million)
- 5.4. Adherent Culture
- 5.4.1. Adherent Culture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Suspension Culture
- 5.5.1. Suspension Culture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. AAV Contract Development And Manufacturing Organizations Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global AAV Contract Development And Manufacturing Organizations Market Application Movement Analysis
- 6.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Cell & Gene Therapy Development
- 6.4.1. Cell & Gene Therapy Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Vaccine Development
- 6.5.1. Vaccine Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Biopharmaceutical and Pharmaceutical Discovery
- 6.6.1. Biopharmaceutical and Pharmaceutical Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Biomedical Research
- 6.7.1. Biomedical Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. AAV Contract Development And Manufacturing Organizations Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global AAV Contract Development And Manufacturing Organizations Market End Use Movement Analysis
- 7.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 7.4. Pharmaceutical and Biopharmaceutical Companies
- 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Academic & Research Institutes
- 7.5.1. Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. AAV Contract Development And Manufacturing Organizations Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use
- 8.1. Regional Market Dashboard
- 8.2. Global Regional Market Snapshot
- 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Competitive Scenario
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Europe
- 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Competitive Scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Competitive Scenario
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Competitive Scenario
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Competitive Scenario
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Competitive Scenario
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Competitive Scenario
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Competitive Scenario
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Competitive Scenario
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8. MEA
- 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Competitive Scenario
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Competitive Scenario
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Competitive Scenario
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Competitive Scenario
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.6. Oman
- 8.8.6.1. Key Country Dynamics
- 8.8.6.2. Competitive Scenario
- 8.8.6.3. Regulatory Framework
- 8.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.7. Qatar
- 8.8.7.1. Key Country Dynamics
- 8.8.7.2. Competitive Scenario
- 8.8.7.3. Regulatory Framework
- 8.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. AAV Contract Development And Manufacturing Organizations Market Share Analysis, 2024
- 9.3. Company Profiles
- 9.3.1. Thermo Fischer Scientific, Inc.
- 9.3.1.1. Company overview
- 9.3.1.2. Financial performance
- 9.3.1.3. Product benchmarking
- 9.3.1.4. Strategic initiatives
- 9.3.2. Creative Biogene
- 9.3.2.1. Company overview
- 9.3.2.2. Financial performance
- 9.3.2.3. Product benchmarking
- 9.3.2.4. Strategic initiatives
- 9.3.3. Catalent Inc
- 9.3.3.1. Company overview
- 9.3.3.2. Financial performance
- 9.3.3.3. Product benchmarking
- 9.3.3.4. Strategic initiatives
- 9.3.4. Charles River Laboratories International, Inc
- 9.3.4.1. Company overview
- 9.3.4.2. Financial performance
- 9.3.4.3. Product benchmarking
- 9.3.4.4. Strategic initiatives
- 9.3.5. Danaher (Aldevron)
- 9.3.5.1. Company overview
- 9.3.5.2. Financial performance
- 9.3.5.3. Product benchmarking
- 9.3.5.4. Strategic initiatives
- 9.3.6. Forge Biologics
- 9.3.6.1. Company overview
- 9.3.6.2. Financial performance
- 9.3.6.3. Product benchmarking
- 9.3.6.4. Strategic initiatives
- 9.3.7. Genezen
- 9.3.7.1. Company overview
- 9.3.7.2. Financial performance
- 9.3.7.3. Product benchmarking
- 9.3.7.4. Strategic initiatives
- 9.3.8. ViroCell Biologics
- 9.3.8.1. Company overview
- 9.3.8.2. Financial performance
- 9.3.8.3. Product benchmarking
- 9.3.8.4. Strategic initiatives
- 9.3.9. Merck KGaA
- 9.3.9.1. Company overview
- 9.3.9.2. Financial performance
- 9.3.9.3. Product benchmarking
- 9.3.9.4. Strategic initiatives
- 9.3.10. VIRALGEN
- 9.3.10.1. Company overview
- 9.3.10.2. Financial performance
- 9.3.10.3. Product benchmarking
- 9.3.10.4. Strategic initiatives
- 9.3.11. Biovian Oy
- 9.3.11.1. Company overview
- 9.3.11.2. Financial performance
- 9.3.11.3. Product benchmarking
- 9.3.11.4. Strategic initiatives
- 9.3.12. Esco Lifesciences (Esco Aster Pte. Ltd.)
- 9.3.12.1. Company overview
- 9.3.12.2. Financial performance
- 9.3.12.3. Product benchmarking
- 9.3.12.4. Strategic initiatives
- 9.3.13. GenScript ProBio
- 9.3.13.1. Company overview
- 9.3.13.2. Financial performance
- 9.3.13.3. Product benchmarking
- 9.3.13.4. Strategic initiatives
- 9.3.14. Porton Advanced Solution Ltd
- 9.3.14.1. Company overview
- 9.3.14.2. Financial performance
- 9.3.14.3. Product benchmarking
- 9.3.14.4. Strategic initiatives
- 9.3.15. Ask Bio
- 9.3.15.1. Company overview
- 9.3.15.2. Financial performance
- 9.3.15.3. Product benchmarking
- 9.3.15.4. Strategic initiatives
- 9.3.16. Showa Denko
- 9.3.16.1. Company overview
- 9.3.16.2. Financial performance
- 9.3.16.3. Product benchmarking
- 9.3.16.4. Strategic initiatives
- 9.3.17. Takara Bio, Inc.
- 9.3.17.1. Company overview
- 9.3.17.2. Financial performance
- 9.3.17.3. Product benchmarking
- 9.3.17.4. Strategic initiatives
- 9.3.18. ABL Manufacturing
- 9.3.18.1. Company overview
- 9.3.18.2. Financial performance
- 9.3.18.3. Product benchmarking
- 9.3.18.4. Strategic initiatives
- 9.3.19. Oxford Biomedica
- 9.3.19.1. Company overview
- 9.3.19.2. Financial performance
- 9.3.19.3. Product benchmarking
- 9.3.19.4. Strategic initiatives
- 9.3.20. Belief Biomed, Inc.
- 9.3.20.1. Company overview
- 9.3.20.2. Financial performance
- 9.3.20.3. Product benchmarking
- 9.3.20.4. Strategic initiatives
- 9.3.21. Beijing Anlong Biomedicine Co., Ltd
- 9.3.21.1. Company overview
- 9.3.21.2. Financial performance
- 9.3.21.3. Product benchmarking
- 9.3.21.4. Strategic initiatives
- 9.3.22. Forecyte Bio Limited
- 9.3.22.1. Company overview
- 9.3.22.2. Financial performance
- 9.3.22.3. Product benchmarking
- 9.3.22.4. Strategic initiatives
- 9.3.23. Gene Pharma, Inc.
- 9.3.23.1. Company overview
- 9.3.23.2. Financial performance
- 9.3.23.3. Product benchmarking
- 9.3.23.4. Strategic initiatives
- 9.3.24. Skyline Therapeutics
- 9.3.24.1. Company overview
- 9.3.24.2. Financial performance
- 9.3.24.3. Product benchmarking
- 9.3.24.4. Strategic initiatives
- 9.3.25. TFBS Bioscience, Inc
- 9.3.25.1. Company overview
- 9.3.25.2. Financial performance
- 9.3.25.3. Product benchmarking
- 9.3.25.4. Strategic initiatives
- 9.3.1. Thermo Fischer Scientific, Inc.
샘플 요청 목록